In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer-Reference-Cited by-同舟云学术

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer

Published:2015-10-15 Issue:36 Volume:6 Page:38789-38803
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Hirano Toshiyuki¹,Yasuda Hiroyuki¹,Tani Tetsuo¹,Hamamoto Junko¹,Oashi Ayano¹,Ishioka Kota¹,Arai Daisuke¹,Nukaga Shigenari¹,Miyawaki Masayoshi¹,Kawada Ichiro¹,Naoki Katsuhiko²,Costa Daniel B.³,Kobayashi Susumu S.³,Betsuyaku Tomoko¹,Soejima Kenzo¹

Affiliation:

1. Division of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan

2. Keio Cancer Center, Keio University, School of Medicine 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan

3. Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, preparation and biological evaluation of new Rociletinib-inspired analogs as irreversible EGFR inhibitors to treat non-small-cell-lung cancer;Bioorganic & Medicinal Chemistry;2024-09

2. Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study;BMC Cancer;2024-08-14

3. A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19);Lung Cancer;2024-08

4. Screening of protein-based inhibitors for the intracellular domain of epidermal growth factor receptor by directed evolution using the yeast Gγ recruitment system;Journal of Bioscience and Bioengineering;2024-08

5. Novel therapeutic strategies for rare mutations in non-small cell lung cancer;Scientific Reports;2024-05-05